Jianjun Xiao

482 total citations
16 papers, 222 citations indexed

About

Jianjun Xiao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jianjun Xiao has authored 16 papers receiving a total of 222 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Jianjun Xiao's work include Advanced Breast Cancer Therapies (4 papers), HER2/EGFR in Cancer Research (4 papers) and Cancer Treatment and Pharmacology (3 papers). Jianjun Xiao is often cited by papers focused on Advanced Breast Cancer Therapies (4 papers), HER2/EGFR in Cancer Research (4 papers) and Cancer Treatment and Pharmacology (3 papers). Jianjun Xiao collaborates with scholars based in China, United States and United Kingdom. Jianjun Xiao's co-authors include Junkai Zhang, Wenjing Dong, Mancheng Gong, Li Li, Yida Zhang, Zhongjun Xia, Jiewen Peng, Dongying Liu, Antonio Gualberto and Dejan Juric and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Jianjun Xiao

15 papers receiving 221 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jianjun Xiao China 9 115 89 75 72 30 16 222
Elie W. Akl United States 7 79 0.7× 104 1.2× 52 0.7× 98 1.4× 18 0.6× 12 230
Frank Ziemann Germany 8 113 1.0× 121 1.4× 58 0.8× 57 0.8× 23 0.8× 10 259
Jaime Miguel Gomes Pita Belgium 7 119 1.0× 142 1.6× 74 1.0× 112 1.6× 15 0.5× 11 318
Zdeněk Pavelka Czechia 10 80 0.7× 148 1.7× 64 0.9× 41 0.6× 15 0.5× 19 277
Jason Kunisaki United States 4 63 0.5× 109 1.2× 98 1.3× 94 1.3× 24 0.8× 6 236
Simona Frezzini Italy 6 93 0.8× 113 1.3× 89 1.2× 42 0.6× 31 1.0× 8 231
Jack Zhu United States 6 72 0.6× 107 1.2× 83 1.1× 97 1.3× 13 0.4× 10 230
Nobuhiko Nishijima Japan 8 110 1.0× 133 1.5× 79 1.1× 143 2.0× 28 0.9× 15 302
Huiyun Cai China 8 110 1.0× 127 1.4× 81 1.1× 31 0.4× 56 1.9× 16 279
Alba Font‐Tello United States 8 54 0.5× 128 1.4× 64 0.9× 88 1.2× 16 0.5× 9 220

Countries citing papers authored by Jianjun Xiao

Since Specialization
Citations

This map shows the geographic impact of Jianjun Xiao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianjun Xiao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianjun Xiao more than expected).

Fields of papers citing papers by Jianjun Xiao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianjun Xiao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianjun Xiao. The network helps show where Jianjun Xiao may publish in the future.

Co-authorship network of co-authors of Jianjun Xiao

This figure shows the co-authorship network connecting the top 25 collaborators of Jianjun Xiao. A scholar is included among the top collaborators of Jianjun Xiao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianjun Xiao. Jianjun Xiao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Tian, Xiaona, et al.. (2025). Disproportionality analysis of drug-induced erectile dysfunction using FAERS database. Scientific Reports. 15(1). 15760–15760. 2 indexed citations
2.
3.
4.
Macarulla, Teresa, Víctor Moreno, Li‐Tzong Chen, et al.. (2021). Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology. 39(15_suppl). 4090–4090. 8 indexed citations
5.
Johnston, Stephen, Timothy Pluard, Judy S. Wang, et al.. (2021). Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer.. Journal of Clinical Oncology. 39(15_suppl). e13025–e13025. 9 indexed citations
6.
7.
8.
Hamilton, Erika, Judy S. Wang, Timothy Pluard, et al.. (2021). Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.. Journal of Clinical Oncology. 39(15_suppl). 1018–1018. 31 indexed citations
9.
Huang, Qiong, Shao-wei Li, Xingbin Hu, et al.. (2020). Shear stress activates ATOH8 via autocrine VEGF promoting glycolysis dependent-survival of colorectal cancer cells in the circulation. Journal of Experimental & Clinical Cancer Research. 39(1). 25–25. 44 indexed citations
10.
Xiao, Jianjun, Xuemei Wang, & Haitao Bai. (2020). Clinical Features and Prognostic Impact of Coexpression Modules Constructed by WGCNA for Diffuse Large B‐Cell Lymphoma. BioMed Research International. 2020(1). 7947208–7947208. 4 indexed citations
11.
Zhang, Yida, et al.. (2017). miR-5195-3p Inhibits Proliferation and Invasion of Human Bladder Cancer Cells by Directly Targeting Oncogene KLF5. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 25(7). 1081–1087. 36 indexed citations
12.
Dong, Wenjing, et al.. (2016). Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies. PLoS ONE. 11(3). e0152448–e0152448. 46 indexed citations
13.
Peng, Jiewen, et al.. (2015). Hepatitis B Virus Infection Is Associated with Poor Prognosis in Patients with Advanced Non Small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention. 16(13). 5285–5288. 15 indexed citations
14.
Lin, Gui‐Nan, Xiaomei Jiang, Jiewen Peng, et al.. (2014). Prognostic Significance of the Peripheral Blood Absolute Monocyte Count in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma Receiving Systemic Chemotherapy. Asian Pacific Journal of Cancer Prevention. 15(15). 6387–6390. 8 indexed citations
15.
Zhang, Junkai, et al.. (2010). [Expression of HER-2/neu oncogene in hepatocellular carcinoma and the clinical implications].. PubMed. 30(2). 326–8. 9 indexed citations
16.
Cheng, Frankie Wai Tsoi & Jianjun Xiao. (2009). Management of Tumour Lysis Syndrome in Non-Hodgkin Lymphoma. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elie W. Akl Breakdown of academic impact, for papers by Frank Ziemann Breakdown of academic impact, for papers by Jaime Miguel Gomes Pita Breakdown of academic impact, for papers by Zdeněk Pavelka Breakdown of academic impact, for papers by Jason Kunisaki Breakdown of academic impact, for papers by Simona Frezzini Breakdown of academic impact, for papers by Jack Zhu Breakdown of academic impact, for papers by Nobuhiko Nishijima Breakdown of academic impact, for papers by Huiyun Cai Breakdown of academic impact, for papers by Alba Font‐Tello
Rankless by CCL
2026